Hydroxychloroquine Improves the Disease Activity and Allows the Reduction of the Corticosteroid Dose Regardless of Background Treatment in Japanese Patients with Systemic Lupus Erythematosus

OBJECTIVE: Hydroxychloroquine (HCQ) was not approved in Japan until 2015, and its therapeutic potential has not been explored in depth. We evaluated the additional therapeutic effect of HCQ in Japanese patients with systemic lupus erythematosus (SLE) on maintenance therapy. METHODS: Patients with SL...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Intern Med
Hoofdauteurs: Hanaoka, Hironari, Iida, Harunobu, Kiyokawa, Tomofumi, Takakuwa, Yukiko, Kawahata, Kimito
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: The Japanese Society of Internal Medicine 2019
Onderwerpen:
Original Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6543229/
https://ncbi.nlm.nih.gov/pubmed/30626831
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2169/internalmedicine.1999-18
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items